<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480740</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 3908</org_study_id>
    <nct_id>NCT00480740</nct_id>
  </id_info>
  <brief_title>The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease</brief_title>
  <official_title>The Pharmacology of Dexmedetomidine in Children With Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the pharmacokinetics, pharmacodynamics, and
      pharmacogenomics of dexmedetomidine in the following three pediatric patient populations:
      patients with bi-directional cavopulmonary anastomosis or a Fontan procedure, patients who
      have had a cardiac transplant, and patients with otherwise normal physiology who are
      undergoing closure of a patent ductus arteriosis or atrial septal defect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While opioid analgesia is currently the mainstream for management of pain in the
      perioperative setting, it often leads to significant morbidity, including opioid tolerance
      and hyperalgesia. Looking at ways to decrease the need for opioids with the use of adjunct
      medications allows for the long-term goal of decreasing physiologic tolerance in children.
      This is especially relevant in the pediatric congenital heart population.

      Dexmedetomidine is in a class of drugs known as alpha-2 agonists and is known to provide
      analgesia, attenuate opioid tolerance and inhibit the sympathetic stress response. While
      there are numerous published case studies of dexmedetomidine validating its effectiveness and
      safety, the pharmacologic and pharmacodynamic profile has not been established.

      This study will examine the hemodynamics, pharmacokinetics, and pharmacogenomics of
      dexmedetomidine in patients with congenital heart disease. The dose-ranging effect of
      dexmedetomidine will also be investigated. The three groups being studied will be: patients
      with bi-directional cavopulmonary anastomosis or a Fontan procedure, patients who have had a
      cardiac transplant, and patients with otherwise normal physiology who are undergoing closure
      of a patent ductus arteriosis or atrial septal defect.

      Comparison: Compare both invasive and noninvasive hemodynamic parameters at baseline
      sevoflurane and during maintenance dosing on dexmedetomidine. The pharmacokinetics of
      dexmedetomidine in the pediatric population following escalating loading doses and continuous
      infusion at timed intervals will be estimated. The efficacy of dexmedetomidine will be
      estimated by the amount of rescue doses of propofol that are given.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hemodynamic Variables Recorded During Administration of Sevoflurane + Dexmedetomidine.</measure>
    <time_frame>Up to 24 hours following cardiac catheterization</time_frame>
    <description>Non-inferiority was shown when differences at steady-state (dexmedetomidine + sevoflurane) compared to baseline (sevoflurane alone) and its associated 95% confidence interval fell completely within the range of plus or minus 20%.The 95% confidence interval was normalized by subtracting the baseline values.
Bispectral Index: monitors electroencephalographic and electromyographic parameters to monitor the depth of anesthesia.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Cardiac Transplant</condition>
  <condition>Patent Ductus Arterious</condition>
  <condition>Atrial Septal Defect</condition>
  <condition>Bidirectional Cavopulmonary Anastomosis</condition>
  <arm_group>
    <arm_group_label>Cardiac Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diagnostic cardiac catheterization in children with a transplanted heart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fontan procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diagnostic cardiac catheterization in children with a transplanted ventricle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Physiology</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>diagnostic cardiac catheterization in children with normal cardiac physiology</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization</description>
    <arm_group_label>Cardiac Transplant</arm_group_label>
    <arm_group_label>Fontan procedure</arm_group_label>
    <arm_group_label>Normal Physiology</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age is birth to 18 years

          -  &gt; or = 6 kg.

          -  American Society of Anesthesiology (ASA) I, II, or III

          -  undergone prior cardiac transplant, Fontan or has a patent ductus arterious or atrial
             septal defect.

          -  scheduled for cardiac catheterization

        Exclusion Criteria:

          -  subject or family history of malignant hyperthermia

          -  known hepatic disorder determined by history physical exam or laboratory tests

          -  pregnant or lactating female

          -  receiving inotropic agents or has a pacemaker

          -  weighs less than 6 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia C Finkel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finkel JC, Johnson YJ, Quezado ZM. The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med. 2005 Sep;33(9):2110-2.</citation>
    <PMID>16148487</PMID>
  </reference>
  <reference>
    <citation>Finkel JC, Elrefai A. The use of dexmedetomidine to facilitate opioid and benzodiazepine detoxification in an infant. Anesth Analg. 2004 Jun;98(6):1658-9, table of contents.</citation>
    <PMID>15155322</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2007</study_first_posted>
  <results_first_submitted>August 19, 2014</results_first_submitted>
  <results_first_submitted_qc>June 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2015</results_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Julia Finkel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Congenital heart disease</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pediatric</keyword>
  <keyword>Bidirectional cavopulmonary anastomosis</keyword>
  <keyword>Fontan physiology</keyword>
  <keyword>Cardiac transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from cardiology outpatient clinic. The study is anticipating to enroll 104 patients.</recruitment_details>
      <pre_assignment_details>74 subjects assessed for eligibility, 9 were excluded; 12 did not meet inclusion criteria; 12 refused to enroll; resulting in 41 subjects enrolled</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Physiology</title>
          <description>diagnostic cardiac catheterization in children with normal cardiac physiology</description>
        </group>
        <group group_id="P2">
          <title>Cardiac Transplant</title>
          <description>diagnostic cardiac catheterization in children with a transplanted heart</description>
        </group>
        <group group_id="P3">
          <title>Fontan Physiology</title>
          <description>diagnostic cardiac catheterization in children with a transplanted ventricle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Physiology</title>
        </group>
        <group group_id="B2">
          <title>Cardiac Transplant</title>
        </group>
        <group group_id="B3">
          <title>Fontan Physiology</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="4"/>
                    <measurement group_id="B2" value="11" spread="4.5"/>
                    <measurement group_id="B3" value="5.5" spread="3.3"/>
                    <measurement group_id="B4" value="6.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="14.3"/>
                    <measurement group_id="B2" value="35.2" spread="17.8"/>
                    <measurement group_id="B3" value="21.4" spread="8.7"/>
                    <measurement group_id="B4" value="27.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiology (ASA) physical status classification</title>
          <description>Category 1 means healthy patient Category 2 means mild systemic disease Category 3 means severe systemic disease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PA with IVS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLHS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unbalanced AVC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiomyopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tricuspid Atresia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DORV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ebstein's anomaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Hemodynamic Variables Recorded During Administration of Sevoflurane + Dexmedetomidine.</title>
        <description>Non-inferiority was shown when differences at steady-state (dexmedetomidine + sevoflurane) compared to baseline (sevoflurane alone) and its associated 95% confidence interval fell completely within the range of plus or minus 20%.The 95% confidence interval was normalized by subtracting the baseline values.
Bispectral Index: monitors electroencephalographic and electromyographic parameters to monitor the depth of anesthesia.</description>
        <time_frame>Up to 24 hours following cardiac catheterization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Physiology</title>
            <description>diagnostic cardiac catheterization in children with normal cardiac physiology</description>
          </group>
          <group group_id="O2">
            <title>Cardiac Transplant</title>
            <description>diagnostic cardiac catheterization in children with a transplanted heart</description>
          </group>
          <group group_id="O3">
            <title>Fontan Physiology</title>
            <description>diagnostic cardiac catheterization in children with a transplanted ventricle</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hemodynamic Variables Recorded During Administration of Sevoflurane + Dexmedetomidine.</title>
          <description>Non-inferiority was shown when differences at steady-state (dexmedetomidine + sevoflurane) compared to baseline (sevoflurane alone) and its associated 95% confidence interval fell completely within the range of plus or minus 20%.The 95% confidence interval was normalized by subtracting the baseline values.
Bispectral Index: monitors electroencephalographic and electromyographic parameters to monitor the depth of anesthesia.</description>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" lower_limit="-0.15" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.2" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.21" lower_limit="-0.22" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.07" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.08" upper_limit="0.28"/>
                    <measurement group_id="O3" value="0.22" lower_limit="0.16" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.13" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.13" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.09" lower_limit="-0.11" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.17" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.03" upper_limit="0.29"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-0.09" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bispectral Index</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.03" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.16" lower_limit="-0.11" upper_limit="0.43"/>
                    <measurement group_id="O3" value="-0.14" lower_limit="-0.42" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of dexmedetomindine plus sevoflurane compared with the baseline (sevoflurane alone) for any given variable was reached when the difference (steady-state [dexmedetomidine + sevoflurane]-baseline [sevoflurane0]/baseline [sevoflurane]0 and its associated 95% confidence interval (CI) fell completely withing the range of +/-20% indicated by the gray column.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>The original study design was powered to achieve at least 80% power to detect noninferiority with the two-tailed alpha level set at 0.05 for data with two measurements.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from study start through followup</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cardiac Transplant</title>
          <description>Dexmedetomidine: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization</description>
        </group>
        <group group_id="E2">
          <title>Fontan Procedure</title>
          <description>Dexmedetomidine: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization</description>
        </group>
        <group group_id="E3">
          <title>Normal Physiology</title>
          <description>control group
Dexmedetomidine: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Julia Finkel</name_or_title>
      <organization>Children's National Medical Center</organization>
      <phone>202-476-4867</phone>
      <email>jfinkel@childrensnational.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

